Gyre Therapeutics, Inc. Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss)
Gyre Therapeutics, Inc. (GYRE) reported Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) of -$1.06 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-08.
Discontinued › Income Statement › Other Income
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss · last filed 2017-03-08
- Gyre Therapeutics, Inc. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for the quarter ending 2016-12-31 was -$21.00K.
- Gyre Therapeutics, Inc. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for the quarter ending 2016-09-30 was -$99.00K.
- Gyre Therapeutics, Inc. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for the quarter ending 2016-06-30 was -$1.81M.
- Gyre Therapeutics, Inc. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for the quarter ending 2016-03-31 was $875.00K.
- Gyre Therapeutics, Inc. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for fiscal 2016 was -$1.06M, a 536.78% decline from fiscal 2015.
- Gyre Therapeutics, Inc. fair value, net derivative asset (liability), recurring basis, still held, unrealized gain (loss) for fiscal 2015 was $242.00K.
| Period end | Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) 3 month | Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) 6 month | Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) 9 month | Fair Value, Net Derivative Asset (Liability), Recurring Basis, Still Held, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2016-12-31 | -$21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-08 | -$120.00K derived: sum of 2 quarters · filed 2017-03-08 | -$1.93M derived: sum of 3 quarters · filed 2017-03-08 | -$1.06M 10-K · filed 2017-03-08 |
| 2016-09-30 | -$99.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$1.91M derived: sum of 2 quarters · filed 2016-11-03 | -$1.04M 10-Q · filed 2016-11-03 | -$1.53M derived: sum of 4 quarters · filed 2016-11-03 |
| 2016-06-30 | -$1.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$937.00K 10-Q · filed 2016-08-04 | -$1.44M derived: sum of 3 quarters · filed 2016-08-04 | |
| 2016-03-31 | $875.00K 10-Q · filed 2016-05-05 | $377.00K derived: sum of 2 quarters · filed 2016-05-05 | ||
| 2015-12-31 | -$498.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-09 | $242.00K 10-K · filed 2016-03-09 | ||
| 2015-09-30 | $740.00K 10-Q · filed 2015-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |